Ocular: 'Buy' As AXPAXLI Program For Wet-AMD Moves To Potential NDA Filing
Seeking Alpha
February 17, 2026
Ocular Therapeutix keeps a "Buy" rating on strong AXPAXLI SOL-1 wet-AMD phase 3 data and FDA/NDA catalysts ahead. Here's what you need to know.
Verticals
financemarkets
Originally published on Seeking Alpha on 2/17/2026